Typhoid vaccine Vi polysaccharide - Finlay InstituteAlternative Names: vax-TyVi; Vi polysaccharide typhoid vaccine - Finlay Institute
Latest Information Update: 17 Nov 2014
At a glance
- Originator Finlay Institute of Cuba
- Class Bacterial vaccines; Polysaccharides
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Marketed Typhoid
Most Recent Events
- 12 Nov 2014 Launched for Typhoid (Prevention; in adults and children) in Cuba (IM) prior to November 2014